Medivir AB could earn about $111 million in up-front and milestone payments from two new drug development licensing deals with Tibotec Pharmaceuticals Ltd. (BioWorld International)

MediGene Shares Slide On FDA PDUFA Date Extension

July 6, 2006

By Cormac Sheridan

Medivir Could Earn $111M Through New Tibotec Deals

July 6, 2006

By Cormac Sheridan

Medivir AB could earn about $111 million in up-front and milestone payments from two new drug development licensing deals with Tibotec Pharmaceuticals Ltd. (BioWorld International)

Ireland Planning To Ramp Up Levels Of Research Spending

June 28, 2006

By Cormac Sheridan

Italy's BioXell Goes Public On Swiss Market, Gets CHF57.8M

June 28, 2006

By Cormac Sheridan

BioXell SpA grossed CHF57.8 million (US$46.3 million) in an initial public offering on the Swiss Stock Exchange in Zurich to fund ongoing clinical and preclinical development of its portfolio of six drug candidates. (BioWorld International)

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
New 5-HT2C receptor agonists reported in Hansoh patent
BioWorld Science
Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...
Parabilis takes top spot, pricing largest biopharma IPO at $670M
BioWorld
Less than two months after Kailera Therapeutics Inc. made headlines with biopharma’s largest IPO to date, Parabilis Medicines Inc. has come along and surpassed...